Interventional Radiology
Recently published international recommendations for use of SIR-Spheres® Y-90 resin microspheres
- Newest publication of its kind focused on Dosimetry
- Fills a major information gap across international clinical communities
- Supports best practices to treat patients collaboratively in a program-based system to improve patient outcomes
- Developed by 43 international and multidisciplinary experts, including 23 members of the steering committee
The SIR-Spheres Advantage empowers practitioners by providing programs and tools to implement these consensus recommendations
Recommendation 23: "For selective ablative treatments, it is recommended to consider a higher specific activity, hence a lower number of microspheres." (Strong consensus)
Recommendation 17: "SIRT should be conducted as soon as possible after the simulation [...]" (Strong consensus)
Recommendation 46: "Post-SIRT dosimetry is recommended." (Strong consensus) / R21-22: "A personalized approach using dosimetry (partition model and/or voxel-based) is recommended for activity prescription." (Strong consensus)
Levillain, H., Bagni, O., Deroose, C.M. et al. International recommendations for personalized selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging 2021; 48(5): 1570-1584.
SIR-Spheres® Y-90 resin microspheres are indicated for the treatment of:
- Unresectable hepatocellular carcinoma (HCC), or
- Unresectable metastatic liver tumors from primary colorectal cancer (mCRC) in patients refractory to or intolerant of chemotherapy, or
- Unresectable intrahepatic cholangiocarcinoma (iCCA), or
- Hepatic metastases by neuroendocrine tumours (mNET), or
- Other liver metastases